GlassScriptPhysician profile
Eric J Rothchild
NPI 1265475289
$1,998.54
in general payments reported to CMS, 2019-2025
20 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.19 · 2020: $153 · 2021: $83.15 · 2022: $122 · 2023: $1,197 · 2024: $258 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $949 · Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $949.33 |
| Food and Beverage | $619.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,097.04 | 2023 | Lensx |
| Rxsight INC | $192.94 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Injector Cartridge |
| Johnson & Johnson Surgical Vision, INC. | $105.43 | 2019-2022 | |
| Dompe US, INC. | $81.79 | 2019-2025 | Oxervate |
| Glaukos Corporation | $78.57 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Biotissue Holdings INC. | $74.62 | 2020-2024 | |
| Allergan, INC. | $63.03 | 2020-2021 | |
| Sight Sciences, INC. | $42.23 | 2023-2024 | Omni Surgical System, Tearcare System |
| Notal Vision, INC. | $34.65 | 2024 | Foresee Home |
| Tarsus Pharmaceuticals, INC. | $28.13 | 2024 | Xdemvy |
| Rayner Intraocular Lenses Limited | $27.11 | 2022 | |
| Oyster Point Pharma, INC. | $25.68 | 2023 | Tyrvaya |
| New World Medical,INC. | $23.07 | 2022 | |
| Astellas Pharma US INC | $21.23 | 2024 | Izervay |
| Eyevance Pharmaceuticals LLC | $19.74 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Bausch & Lomb Americas INC. | $18.52 | 2024 | Miebo |
| Novartis Pharmaceuticals Corporation | $17.79 | 2020 | |
| Aerie Pharmaceuticals, INC. | $14.58 | 2021 | |
| Abbvie INC. | $12.99 | 2023 | Durysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Rothchild listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.